These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22185662)

  • 1. A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma.
    Warsch S; Hosein PJ; Maeda LS; Alizadeh AA; Lossos IS
    Leuk Lymphoma; 2012 Jul; 53(7):1299-1305. PubMed ID: 22185662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
    Ohmachi K; Ando K; Ogura M; Uchida T; Itoh K; Kubota N; Ishizawa K; Yamamoto J; Watanabe T; Uike N; Choi I; Terui Y; Usuki K; Nagai H; Uoshima N; Tobinai K;
    Cancer Sci; 2010 Sep; 101(9):2059-64. PubMed ID: 20626754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
    Ogura M; Uchida T; Taniwaki M; Ando K; Watanabe T; Kasai M; Matsumoto Y; Shimizu D; Ogawa Y; Ohmachi K; Yokoyama H; Tobinai K;
    Cancer Sci; 2010 Sep; 101(9):2054-8. PubMed ID: 20594195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
    Weide R; Hess G; Köppler H; Heymanns J; Thomalla J; Aldaoud A; Losem C; Schmitz S; Haak U; Huber C; Unterhalt M; Hiddemann W; Dreyling M;
    Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bendamustine Plus Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Low-grade B-cell Lymphoma and Mantle Cell Lymphoma: A Single-Center Retrospective Study.
    Murakami H; Yoshioka T; Moriyama T; Ishikawa T; Makita M; Sunami K
    Acta Med Okayama; 2021 Aug; 75(4):461-469. PubMed ID: 34511613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma.
    Vacirca JL; Acs PI; Tabbara IA; Rosen PJ; Lee P; Lynam E
    Ann Hematol; 2014 Mar; 93(3):403-9. PubMed ID: 23955074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.
    Friedberg JW; Vose JM; Kelly JL; Young F; Bernstein SH; Peterson D; Rich L; Blumel S; Proia NK; Liesveld J; Fisher RI; Armitage JO; Grant S; Leonard JP
    Blood; 2011 Mar; 117(10):2807-12. PubMed ID: 21239695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bendamustine: a review of its use in the management of indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
    Garnock-Jones KP
    Drugs; 2010 Sep; 70(13):1703-18. PubMed ID: 20731477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience.
    García-Noblejas A; Martínez Chamorro C; Navarro Matilla B; Da Silva Rodriguez C; González-Lopez TJ; Oña Navarrete R; Ramírez Sánchez MJ; Martínez Barranco P; Sánchez Blanco JJ; Nicolás C; Pérez R; Sánchez González B; Ruedas López AM; Domingo-Domenech E; Panizo C; Macia S; Fernández-Fonseca E; Cannata-Ortiz J; Arranz R
    Ann Hematol; 2014 Sep; 93(9):1551-8. PubMed ID: 24782117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.
    Ogura M; Ishizawa K; Maruyama D; Uike N; Ando K; Izutsu K; Terui Y; Imaizumi Y; Tsukasaki K; Suzuki K; Izumi T; Usuki K; Kinoshita T; Taniwaki M; Uoshima N; Suzumiya J; Kurosawa M; Nagai H; Uchida T; Fukuhara N; Choi I; Ohmachi K; Yamamoto G; Tobinai K;
    Int J Hematol; 2017 Apr; 105(4):470-477. PubMed ID: 27900638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation.
    Visco C; Finotto S; Zambello R; Paolini R; Menin A; Zanotti R; Zaja F; Semenzato G; Pizzolo G; D'Amore ES; Rodeghiero F
    J Clin Oncol; 2013 Apr; 31(11):1442-9. PubMed ID: 23401442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice.
    Becker M; Tschechne B; Reeb M; Schwinger U; Bruch HR; Frank M; Straßl L
    Ann Hematol; 2015 Sep; 94(9):1553-8. PubMed ID: 26122866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Routine use of bendamustine and rituximab combination therapy in consecutive patients with lymphoproliferative diseases: a survey from Tyrolean hospitals.
    Waldthaler C; Stauder R; Schnallinger M; Schreieck S; Hager J; Oexle H; Zangerl G; Verdorfer I; Zabernigg A; Gastl G; Fiegl M
    Wien Klin Wochenschr; 2011 May; 123(9-10):269-75. PubMed ID: 21479652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
    Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
    Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Soluble Interleukin-2 Receptor and C-Reactive Protein with the Efficacy of Bendamustine Salvage Treatment for Indolent Lymphomas and Mantle Cell Lymphoma.
    Kawaguchi Y; Nakamaki T; Abe M; Baba Y; Murai S; Watanuki M; Arai N; Fujiwara S; Kabasawa N; Tsukamoto H; Uto Y; Ariizumi H; Yanagisawa K; Hattori N; Harada H; Saito B
    Acta Haematol; 2018; 139(1):12-18. PubMed ID: 29301121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bendamustine and rituximab in relapsed and refractory hairy cell leukemia.
    Burotto M; Stetler-Stevenson M; Arons E; Zhou H; Wilson W; Kreitman RJ
    Clin Cancer Res; 2013 Nov; 19(22):6313-21. PubMed ID: 24097860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.
    Moskowitz AJ; Hamlin PA; Perales MA; Gerecitano J; Horwitz SM; Matasar MJ; Noy A; Palomba ML; Portlock CS; Straus DJ; Graustein T; Zelenetz AD; Moskowitz CH
    J Clin Oncol; 2013 Feb; 31(4):456-60. PubMed ID: 23248254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study.
    Matsumoto K; Takayama N; Aisa Y; Ueno H; Hagihara M; Watanabe K; Nakaya A; Chen K; Shimizu T; Tsukada Y; Yamada Y; Nakazato T; Ishida A; Miyakawa Y; Yokoyama K; Nakajima H; Masuda Y; Yano T; Okamoto S;
    Int J Hematol; 2015 Jun; 101(6):554-62. PubMed ID: 25783753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma.
    Cheson BD; Friedberg JW; Kahl BS; Van der Jagt RH; Tremmel L
    Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):452-7. PubMed ID: 21189660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.
    Czuczman MS; Goy A; Lamonica D; Graf DA; Munteanu MC; van der Jagt RH
    Ann Hematol; 2015 Dec; 94(12):2025-32. PubMed ID: 26411584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.